Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35-85
SponsorRarecells Diagnostics SAS
About this trial
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female aged between 35 and 85 years
Patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer.
Patient capable of giving free, informed, and express consent
Exclusion of detectable extra thoracic and distant metastases
Disqualifiers
Patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration
Patient treated with neoadjuvant treatment
Pregnant women
Patient presenting psychiatric or neurological disorders preventing them from understanding the research
Trial population
Patients with a diagnosis of lung cancer, planned for lung resection with curative intent.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
CTC-DNA
Diagnostic testctDNA for the analysis of lung cancer mutations in patients with operable tumors.
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: Patient with early lung cancer1 intervention
Trial outcomes
Primary outcomes
1
Comparative and complementary in operable patients diagnosed with cancer
Number of patients with lung cancer-related mutations by CTCDNA alone, by ctDNA alone and by the ctDNA -CTCDNA pair divided by the number of patients with cancer enrolled in the study
Time frame
30 days post procedureSecondary outcomes
1
Comparative and complementary sensitivity of CTC-DNA and ctDNA per histological subtype
Number of patients with lung cancer-related mutations by CTCDNA alone, by ctDNA alone and by the ctDNA -CTCDNA pair per histologic subtype
Time frame
30 days post procedureSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov